Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)
2.105
-0.185
(-8.08%)
Streaming Delayed Price
Updated: 12:16 PM EDT, Apr 4, 2025
Add to My Watchlist
All News about Relay Therapeutics, Inc. - Common Stock

Via Benzinga

AI Surge Ending: Only One Category Was Up This Week
April 06, 2024
Via Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence



Relay Therapeutics to Participate in Three Upcoming Investor Conferences
February 26, 2024
Via GlobeNewswire

Relay Therapeutics: Q4 Earnings Insights
February 22, 2024
Via Benzinga

Relay Therapeutics's Earnings: A Preview
February 21, 2024
Via Benzinga


AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
Via Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence



Relay Therapeutics's Earnings Outlook
November 01, 2023
Via Benzinga



Relay Therapeutics Announces $30 Million Private Placement Financing
January 08, 2024
Via GlobeNewswire




12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 13, 2023
Via Benzinga



Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
December 06, 2023
Via Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence

Unlocking AI investment opportunities in healthcare
November 16, 2023
Via MarketBeat
Exposures
Artificial Intelligence


Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
November 07, 2023
Via GlobeNewswire



12 Health Care Stocks Moving In Thursday's After-Market Session
October 12, 2023
Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free